Esperion Therapeutics ESPR Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $80.1M-52.4% | $168.45M+92.9% | $87.31M+6.0% | $82.39M+26.8% | $65M-6.0% | ||
| $8.99M-35.5% | $13.93M-1.5% | $14.13M+95.2% | $7.24M-42.4% | $12.56M+14.4% | ||
| $43.12M+4.1% | $41.43M-1.0% | $41.85M+5.9% | $39.51M-8.1% | $43M+16.4% | ||
| $86.69M+4.2% | $83.21M-14.4% | $97.27M+29.2% | $75.29M-13.6% | $87.09M+18.4% | ||
| —— | $32.31M0.0% | $32.31M0.0% | $32.31M0.0% | $32.31M+88.4% | ||
| -$6.58M-108% | $85.23M+956% | -$9.96M-240% | $7.1M+132% | -$22.1M— | ||
| -8.2%-58.8pp | 50.6%+62.0pp | -11.4%-20.0pp | 8.6%+42.6pp | -34%-34.0pp | ||
| $19.8M-12.5% | $22.64M+2.7% | $22.05M+7.6% | $20.49M+5.4% | $19.43M+18.3% | ||
| $1.18M+10.0% | $1.08M+58.8% | $677K+1.7% | $666K-37.9% | $1.07M-11.2% | ||
| —— | -$5.21M0.0% | -$5.21M0.0% | -$5.21M0.0% | -$5.21M+59.7% | ||
| —— | $460.25K0.0% | $460.25K0.0% | $460.25K0.0% | $460.25K— | ||
| -$25.2M— | —— | -$31.33M-146% | -$12.73M+68.5% | -$40.46M-89.8% | ||
| -31.5%— | —— | -35.9%-20.4pp | -15.4%+46.8pp | -62.2%-31.4pp | ||
| -$0.10— | —— | -$0.16-167% | -$0.06+71.4% | -$0.21-90.9% | ||
| -$6.55M-108% | $85.26M+958% | -$9.93M-239% | $7.12M+132% | -$22.07M-81,841% | ||
| -8.2%-58.8pp | 50.6%+62.0pp | -11.4%-20.0pp | 8.6%+42.6pp | -34%-34.0pp | ||
| -$6.58M-108% | $85.23M+956% | -$9.96M-240% | $7.1M+132% | -$22.1M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Esperion Therapeutics's revenue?
- Esperion Therapeutics (ESPR) generated $418.2M in revenue over the trailing twelve months, up 61.1% year over year.
- Is Esperion Therapeutics profitable?
- Esperion Therapeutics is not currently profitable: it reported a net loss of $109.7M over the trailing twelve months, a -34.8% net margin.
- What is Esperion Therapeutics's earnings per share?
- Esperion Therapeutics's diluted EPS over the trailing twelve months is $-0.53.
- Where does Esperion Therapeutics's income statement data come from?
- Every line is extracted from Esperion Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
